IndraLab
Statements
sparser
"While mutation of KRAS , NRAS, and BRAF are associated with poor response to anti‐EGFR monoclonal antibodies [ xref ], [ xref ], [ xref ], approximately 40% of patients that do not respond to anti‐epidermal growth factor receptor (EGFR) therapies are KRAS , NRAS , and BRAF wild‐type [ xref ], suggesting a role for other oncogenic drivers."